# Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

> **NCT02105766** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 56 (actual)

## Conditions studied

- Sickle Cell Disease
- Thalassemia
- Stem Cell Transplantation
- Graft vs Host Disease

## Interventions

- **DRUG:** Alemtuzumab
- **DRUG:** Sirolimus
- **DRUG:** Cyclophosphamide
- **DRUG:** Pentostatin
- **PROCEDURE:** Radiotherapy
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT02105766
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-04-21
- **Primary completion:** 2023-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-03-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02105766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02105766, "Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02105766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*